for subscribers

Editorial | Well done, but move faster on vaccines

Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
0:00
play article
Subscribers can listen to this article
SOPA Images/Getty

After the embarrassment of President Cyril Ramaphosa’s presence at the airport for the arrival of vaccines that ended up not being appropriate for use, the South African government tried again this week and successfully received 80 000 vaccine doses.

It was the first step towards vaccinating front line workers with the first batch of vaccines as part of an implementation study called Sisonke – a phase 3b “real-world” clinical trial spearheaded by the SA Medical Research Council.

A total of 500 000 Johnson & Johnson vaccines will be made available over the next four weeks for step one of the vaccine roll-out plan. The vaccine, which has been proven to be safe, offers 57% efficacy against the 501Y.V2 variant, which is dominant in South Africa. Furthermore, it offers 85% protection against severe illness.

There’s more to this story
Subscribe to News24 and get access to our exclusive journalism and features today.
Subscribe
Already a subscriber? Sign in

E-Editions

Read the digital editions of City Press here.
Read now
Voting Booth
Covid-19 variant, 501Y.V2, has attracted much negative coverage, but as researchers learn more about the variant they are discovering that positives can also be gleaned like the fact that those infected by the variant are showing signs of immunity against re-infection.
Please select an option Oops! Something went wrong, please try again later.
Results
Hoping we learn more soon
30% - 7 votes
We need more scientists
17% - 4 votes
Knowledge is power
39% - 9 votes
Not interested
13% - 3 votes
Vote